| NCT07177066 | A Study of EDG-15400 in Healthy Adults | RECRUITING | PHASE1 | 2025-08-20 | 2026-05 | 2026-05 |
| NCT07034768 | A Study to Evaluate EDG-7500 in People With Renal Impairment | RECRUITING | PHASE1 | 2025-07-22 | 2025-12-31 | 2025-12-31 |
| NCT06916897 | A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers | COMPLETED | PHASE1 | 2025-01-08 | 2025-02-22 | 2025-02-22 |
| NCT06738836 | A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 | COMPLETED | PHASE1 | 2024-12-03 | 2025-01-17 | 2025-01-17 |
| NCT06347159 | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) | RECRUITING | PHASE2 | 2024-04-11 | 2026-03 | 2026-03 |
| NCT06100887 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-03-22 | 2025-10 | 2025-10 |
| NCT06066580 | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION | PHASE2 | 2023-11-02 | 2029-08 | 2029-08 |
| NCT06011317 | A Study of EDG-7500 in Healthy Adults | COMPLETED | PHASE1 | 2023-08-14 | 2024-06-20 | 2024-05-23 |
| NCT05730842 | Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers | COMPLETED | PHASE1 | 2023-01-12 | 2023-04-06 | 2023-04-06 |
| NCT05540860 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-10-24 | 2026-02 | 2026-02 |
| NCT05492734 | A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling | COMPLETED | PHASE1 | 2022-08-12 | 2022-08-19 | 2022-08-19 |
| NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-07-06 | 2026-08 | 2026-08 |
| NCT05160415 | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy | COMPLETED | PHASE1 | 2021-12-28 | 2024-03-01 | 2024-03-01 |
| NCT04585464 | A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults | COMPLETED | PHASE1 | 2020-10-12 | 2021-12-27 | 2021-11-15 |